4 completed, 3 recruiting, 2 unknown, 1 active not recruiting. 12 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 4, Recruiting 3, Unknown 2, Active not recruiting 1, Suspended 1, Terminated 1 |
| Phase 1 | 2 | Completed 1, Suspended 1 |
Follow Advanced Colorectal Carcinoma: new trials by email Literature Review of Advanced Colorectal Carcinoma trials Research Report on Advanced Colorectal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer Serplulimab, Chemotherapy, SABR - Advanced Colorectal Carcinoma, Immunotherapy | Phase 2 | Recruiting | Fudan University | 208 | 2025-03-01 | 2025-03-14 |
| First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer OH2, Capecitabine, Bevacizumab - Advanced Colorectal Carcinoma | Phase 2 | Terminated | Binhui Biopharmaceutical Co., Ltd. | 7 | 2023-10-17 | 2024-04-30 |
| At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment - Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 220 | 2023-08-23 | 2026-04-20 |
| CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Biospecimen Collection, Computed Tomography, Devimistat - Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Northwestern University | 94 | 2023-03-08 | 2023-03-10 |
| A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer VS-6766/avutometinib, Cetuximab, Pill Diary - Colorectal Cancer, Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Suspended | University of Chicago | 53 | 2022-08-22 | 2026-05-08 |
| Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy Fruquintinib, Hepatic Arterial Infusion Chemotherapy - Advanced Colorectal Carcinoma, Liver Metastasis Colon Cancer | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 27 | 2022-02-25 | 2022-06-06 |
| Combining Epigenetic And Immune Therapy to Beat Cancer. Durvalumab, Tazemetostat - Advanced Solid Tumor, Advanced Colorectal Carcinoma | Phase 2 | Completed | Institut Bergonié | 164 | 2021-07-23 | 2026-03-06 |
| Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer Fruquintinib and raltitrexed, Fruquintinib - Advanced Colorectal Carcinoma | Phase 2 | Unknown | Fudan University | 136 | 2020-09-28 | 2021-10-26 |
| TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride - Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 42 | 2019-12-27 | 2026-02-10 |
| Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer Danvatirsen, Durvalumab - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2017-03-02 | 2025-05-06 |
| 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma 4SC-201(Resminostat), FOLFIRI - Advanced Colorectal Carcinoma | Phase 1 / Phase 2 | Completed | 4SC AG | 17 | 2011-01-01 | 2015-04-01 |
| Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma MGN1703, Placebo - Advanced Colorectal Carcinoma | Phase 2 | Completed | Mologen AG | 59 | 2010-06-01 | 2014-06-20 |
Colorectal Neoplasms (6) · Pancreatic Neoplasms (3) · Lung Neoplasms (2) · Adenocarcinoma of Lung (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Ovarian Neoplasms (1) · Rectal Neoplasms (1) · Sarcoma (1) · Tertiary Lymphoid Structures (1) · Turcot syndrome (1)
Neoplasms (7) · Colonic Diseases (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gastrointestinal Diseases (6) · Gastrointestinal Neoplasms (6) · Intestinal Diseases (6) · Intestinal Neoplasms (6) · Neoplasms by Site (6) · Rectal Diseases (6) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Neoplasms by Histologic Type (3) · Pancreatic Diseases (3) · Lung Diseases (2)
Bevacizumab (2) · Disulfides (2) · HMPL-013 (2) · durvalumab (2) · Capecitabine (1) · Cetuximab (1) · Drug Therapy (1) · Fluorouracil (1) · Gemcitabine (1) · Home Care Services (1) · House Calls (1) · Hydroxychloroquine (1) · IFL protocol (1) · Immunoglobulin G (1) · Immunologic Factors (1)
Fudan University (2) · 4SC AG (1) · Binhui Biopharmaceutical Co., Ltd. (1) · Institut Bergonié (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Mologen AG (1) · Northwestern University (1) · Peking University Cancer Hospital & Institute (1) · Roswell Park Cancer Institute (1) · University of Chicago (1)
United States (5) · China (4) · France (2) · Germany (2) · Austria (1) · Czechia (1) · Russia (1) · United Kingdom (1)
Ardaman S. Shergill, MD (1) · Christos Fountzilas, MD (1) · David S Hong (1) · Devalingam Mahalingam (1) · Hans-Joachim Schmoll (1) · Roxana S. Dronca, MD (1) · Weijian Guo (1)
PMID 29946728, PMID 31999946, PMID 39244627, PMID 39886125, PMID 9006748
2009 (1), 2019 (1), P30CA060553 (1)